Antibacterial and osteogenic activities of clindamycin-releasing mesoporous ailica/carboxymethyl chitosan composite hydrogels
Cite this dataset
Sungkhaphan, Piyarat et al. (2021). Antibacterial and osteogenic activities of clindamycin-releasing mesoporous ailica/carboxymethyl chitosan composite hydrogels [Dataset]. Dryad. https://doi.org/10.5061/dryad.k0p2ngf88
Conventional treatment of jaw bone infection is often ineffective to control bacterial infection and enhance bone regeneration. Biodegradable composite hydrogels comprised carboxymethyl chitosan (CMCS) and clindamycin (CDM)-loaded mesoporous silica nanoparticles (MCM-41), possessing dual antibacterial activity and osteogenic potency, were developed in the present study. CDM was successfully loaded into both untreated and plasma-treated MCM-41 nanoparticles, denoted as (p)-MCM-41, followed by the incorporation of each of CDM-loaded (p)-MCM-41 into CMCS. The resulting CDM-loaded composite hydrogels, (p)-MCM-41-CDM-CMCS, demonstrated slow degradation rates (about 70% remaining weight after 14-day immersion), while the CDM-free composite hydrogel entirely disintegrated after 4-day immersion. The plasma treatment was found to improve drug loading capacity and slow down initial drug burst effect. The prolonged releases of CDM from both (p)-MCM-41-CDM-CMCS retained their antibacterial effect against Streptococcus sanguinis for at least 14 days in vitro. In vitro assessment of osteogenic activity showed that the CDM-incorporated composite hydrogel was cytocompatible to human mesenchymal stem cells (hMSCs) and induced hMSC mineralization via p38-dependent upregulated alkaline phosphatase activity. In conclusion, novel (p)-MCM-41-CDM-CMCS hydrogels with combined controlled release of CDM and osteogenic potency were successfully developed for the first time, suggesting their potential clinical benefit for treatments of intraoral bone infection.